Based on the information available, there is some evidence to suggest that certain bacteria may be more prone to developing resistance to the antibiotic tigecycline. According to a study published in the journal Diagnostic Microbiology and Infectious Disease, researchers found that Acinetobacter baumannii and Pseudomonas aeruginosa were the most common bacteria to develop resistance to tigecycline [1]. However, it is important to note that the development of antibiotic resistance is a complex process that can be influenced by a variety of factors, including the overuse or misuse of antibiotics, poor infection control practices, and the genetic makeup of the bacteria itself.

Tigecycline is a broad-spectrum antibiotic that is used to treat a variety of infections, including complicated skin and skin structure infections, complicated intra-abdominal infections, and community-acquired bacterial pneumonia. It is a derivative of tetracycline and works by inhibiting the bacterial protein synthesis.

According to DrugPatentWatch.com, tigecycline is currently off-patent in the United States, which means that generic versions of the drug are available [2]. This may increase access to the drug and potentially reduce its cost, which could help to improve its use and reduce the development of resistance. However, it is important to note that the use of any antibiotic, including tigecycline, should be guided by appropriate prescribing guidelines and infection control practices to minimize the development of resistance.

In summary, based on the available information, there are certain bacteria that may be more prone to developing resistance to tigecycline, such as Acinetobacter baumannii and Pseudomonas aeruginosa. The drug is currently off-patent in the United States, which may increase access to the drug and potentially reduce its cost. However, it is important to use tigecycline and all antibiotics appropriately to minimize the development of resistance.

Sources:

1. [Antimicrobial resistance patterns of tigecycline against clinical isolates in a tertiary care hospital in India](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6394532/). Diagnostic Microbiology and Infectious Disease.
2. [Tigecycline](https://www.drugpatentwatch.com/drugs/tigecycline). DrugPatentWatch.com.